Sonoma Pharmaceuticals Announces Partnership with Global Healthcare Distributor for Distribution of Wound Care Products in the United States

Rhea-AI Summary

Sonoma Pharmaceuticals (Nasdaq: SNOA) has announced a distribution agreement with a leading global healthcare distributor for its wound care products in the United States. The partnership will leverage the distributor's extensive network of hospital systems and healthcare channels to expand Sonoma's wound care business across the country.

Sonoma's products are based on their patented Microcyn® technology, which uses stabilized hypochlorous acid (HOCl) for various applications including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care. CEO Amy Trombly described the partnership as a "huge step forward" for the company's U.S. wound care business expansion.

Additional details about the agreement can be found in Sonoma's Current Report on Form 8-K filed with the SEC on August 21, 2024.

Positive

• Partnership with a leading global healthcare distributor for U.S. market expansion
• Access to an extensive network of hospital systems and healthcare channels
• Potential for increased distribution and sales of wound care products

Negative

• None.

BOULDER, CO / ACCESSWIRE / August 21, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn^® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced that it has entered into a distribution agreement with a leading global healthcare distributor for the marketing and distribution of its wound care products in the United States.

The agreement provides for the distribution of Sonoma's wound care products through an existing and extensive network of hospital systems and other healthcare channels in the United States.

"This partnership represents a huge step forward in the expansion of our wound care business in the United States," said Amy Trombly, CEO of Sonoma. "We are looking forward to working with a leading U.S.-based healthcare company, whose extensive distribution network will bring the benefits of our Microcyn technology to hospitals and other healthcare settings across the country."

Further information about the partnership can be found in the Current Report on Form 8-K filed by Sonoma with the U.S. Securities and Exchange Commission on August 21, 2024.

About Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact busdev@sonomapharma.com.

Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "develop," "anticipate," "expect" and "expand," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs, fund further development, as well as uncertainties relative to the COVID-19 pandemic and economic development, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.

Sonoma Pharmaceuticals^™ and Microcyn^® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.

Media and Investor Contact:

Sonoma Pharmaceuticals, Inc.
ir@sonomapharma.com

Website: www.sonomapharma.com

Follow us on LinkedIn: https://www.linkedin.com/company/sonoma-pharmaceuticals

Follow us on Instagram: https://www.instagram.com/sonomapharma_us/

Follow us on Facebook: https://www.facebook.com/sonomapharma/

SOURCE: Sonoma Pharmaceuticals, Inc.

View the original press release on accesswire.com

FAQ

What new partnership did Sonoma Pharmaceuticals (SNOA) announce on August 21, 2024?

Sonoma Pharmaceuticals announced a distribution agreement with a leading global healthcare distributor for marketing and distributing its wound care products in the United States.

How will the new partnership benefit Sonoma Pharmaceuticals (SNOA)?

The partnership will provide Sonoma access to an extensive network of hospital systems and healthcare channels in the United States, potentially expanding its wound care business and increasing product distribution.

What is the core technology behind Sonoma Pharmaceuticals' (SNOA) products?

Sonoma's products are based on their patented Microcyn® technology, which uses stabilized hypochlorous acid (HOCl) for various healthcare applications.

Where can investors find more information about Sonoma Pharmaceuticals' (SNOA) new distribution agreement?

Further information about the partnership can be found in the Current Report on Form 8-K filed by Sonoma with the U.S. Securities and Exchange Commission on August 21, 2024.